CORXEL’s Dr. Bo Liang on why small molecule oral therapies will be the long-term winners in a GLP-1 market driven by consumer preference.

CORXEL’s Dr. Bo Liang on why efficacy is no longer obesity medicine's biggest gap — and the four unmet needs that define what comes next.

Real-world data from Novo's Octane study show patients who switched from injectable GLP-1 therapy to oral semaglutide lost an average of 4.1% of their body weight within three months.

Numerof's Michael Abrams on why directing employees to the most effective, economical clinicians is digital health's most valuable offering.

Numerof's Michael Abrams on why digital health's cost-savings claims often don't hold up to scrutiny — and why the evidence gap matters.

Numerof's Michael Abrams on why digital health's point-solution era is ending — and why consolidation into broader platforms is the next step.

Numerof's Michael Abrams on why healthcare consolidation is the primary driver of rising employer costs — and why there's no end in sight.

Foghorn Therapeutics and Eli Lilly discontinue their SMARCA2 degrader program, Novartis licenses Abogen's autoimmune mRNA therapy while AstraZeneca, Daiichi Sankyo, and Summit Therapeutics team up on a breast cancer combination trial, and Corxel's Bo Liang makes the case for oral GLP-1 therapies.